Born in Munich, he first studied economics and graduated in business administration at the Ludwig-Maximilians-University in 1995. As he was involved with the stock market at a very early stage, he now has more than 30 years of experience in the capital markets. In the historic dot.com year 2000, he trained as a CEFA analyst in Frankfurt and has since then accompanied over 20 IPOs in Germany.
Until 2018, he held various positions at banks as an asset manager, capital market and macro expert as well as fundamental equity analyst. He is passionate about the energy, commodity and technology markets as well as the tactical and strategic asset allocation of liquid investment products. As an expert speaker at investment committee meetings of funds as well as at customer events, he can still describe the course of the 1987 crash, one of the major buying opportunities of the last 33 years on the stock market.
Today, he knows that the profit in shares is not necessarily the result of buying cheaply, but above all of avoiding mistakes and recognizing in good time when markets are ready to let air out. After all, in addition to basic fundamental analysis, investing in stocks is above all a phenomenon of global liquidity and this must be monitored regularly.
Commented by André Will-Laudien
Commented by André Will-Laudien on June 30th, 2025 | 07:35 CEST
Takeover fever! Biotech and artificial intelligence boost Evotec, NetraMark Holdings, Novo Nordisk, and Bayer
The biotech sector is currently undergoing an exciting transformation, as big data and artificial intelligence are rapidly changing the way new drugs are discovered, developed, and tested. The use of learning algorithms allows molecular target structures to be identified more quickly and potential active ingredients to be evaluated more efficiently. Start-ups and established players alike are increasingly turning to data-driven platforms to reduce research costs and increase the success rate of clinical trials. As a result, capital is increasingly flowing into companies that use modern data analysis to drive biotechnology. Approaches that enable personalized medicine - treatments precisely tailored to an individual's specific condition - are in particularly high demand. For investors, this represents a promising growth sector with enormous disruptive potential. But who are the most interesting players?
Read
Commented by André Will-Laudien on June 26th, 2025 | 07:00 CEST
New biotech boom ignites: Are Evotec, BioNxt, Bayer, Novo Nordisk, and Formycon poised for the next price surge?
The biotechnology industry is currently experiencing a remarkable renaissance. Innovations in personalized medicine, advances in mRNA technologies, and new therapeutic approaches to cancer and autoimmune diseases are fueling investor interest worldwide. In this dynamic environment, established players such as Evotec and Bayer, as well as specialized up-and-comers like BioNxt and Formycon, are moving into the spotlight of strategic investments. While Evotec scores with its strong partner network, Bayer is working on a realignment with a focus on promising research. BioNxt impresses with a lean business model and promising pipeline products in the field of drug delivery. Formycon, on the other hand, is benefiting from the biosimilar boom and is currently undergoing a turnaround. The industry is highly innovation-driven, and those who bet on the right players could reap above-average rewards.
Read
Commented by André Will-Laudien on June 25th, 2025 | 07:10 CEST
Geopolitical wild card: Almonty on track for another price surge, overtaking Rheinmetall, Hensoldt, and RENK
Almonty Industries (TSX: AII; WKN: A1JSSD; ISIN: CA0203981034; CAD 3.23) remains in the spotlight, and rightly so! The tungsten resource stock has been one of the absolute top performers so far in 2025 and has the potential to move into a completely new league. All signs point to a revaluation. What is developing here is more than just a mining project; it is a geopolitically highly relevant raw materials offensive with billion-dollar potential. Amid escalating trade conflicts, China is sending a strategic counter-signal and restricting exports of key metals. Tungsten is thus becoming a critical element for high-tech, aviation, and defense and is now at the top of governments' procurement lists. This is precisely where Almonty comes in. With the Sangdong mine in South Korea, the largest Western tungsten supplier outside China will be established by 2025. US defense companies are already securing the coveted resources – long-term, exclusively, and strategically. The confidence is huge, and the timing is perfect. Those who get in now could ride the next wave of growth. A surge in valuation is more than just likely; it is inevitable!
Read
Commented by André Will-Laudien on June 23rd, 2025 | 07:05 CEST
High-tech boom 3.0! Is another 100% possible with Palantir, SAP, MiMedia, and TeamViewer?
Artificial intelligence and big data remain the big topics on the stock markets alongside defense. This is leading to daily gains for high-tech and defense stocks. Investors increasingly appear to view the capital markets as a one-way street, with valuations seemingly taking a back seat. Interestingly, Europe is ahead of the US. Since the tariff dip in April alone, the EURO STOXX 50 has gained around 20%. With Israel's attack on Iran, some uncertainty is now entering the market. However, many investors do not believe the big bull market will change. Only the Shiller P/E ratio for the S&P 500, at over 36, is a cause for caution, given that the long-term average is around 17. But does anyone care? The party is in full swing, and critics are not welcome. So, where do the opportunities lie in the weeks ahead?
Read
Commented by André Will-Laudien on June 19th, 2025 | 07:00 CEST
Biotech: Weight loss and cancer – Takeovers ahead! Keep an eye on Evotec, Vidac Pharma, Eli Lilly, and Novo Nordisk!
For nearly two years, the biotech sector remained largely stagnant. But in the last few weeks, some heavily bombed-out life science stocks have seen significant gains, and takeovers are back on the agenda. Eli Lilly is acquiring Verve Therapeutics, and BioNTech has finally reached an agreement with CureVac. The carousel is slowly starting to turn, and tensions are rising. New rumors are circulating, especially as major pharma stocks like Eli Lilly and Novo Nordisk are showing negative 12-month performance - despite record highs in the major indices.
What is next?
Commented by André Will-Laudien on June 17th, 2025 | 07:20 CEST
Cement 2.0: Argo Living Soils makes concrete smarter and more climate-friendly
Global CO₂ emissions are a significant contributor to global climate change. In addition to global transportation and energy use, the construction industry, particularly through concrete and cement, also plays a major role. According to a 2022 study by UNEP, the construction sector accounts for around 37% of global CO₂ emissions. Decarbonizing construction is, therefore, a key task in meeting international climate targets. With the founding of a specialized subsidiary and the use of bio-graphene, Canadian company Argo Living Soils is venturing into the concrete industry and combining ecological innovation with industrial scalability. It is worth taking a closer look because the potential is enormous!
Read
Commented by André Will-Laudien on June 17th, 2025 | 07:05 CEST
Takeovers! A new dawn for biotech companies – Evotec, BioNTech, PanGenomic Health, and CureVac in focus
Many large pharmaceutical companies are facing the "patent cliff" as patents on blockbuster drugs expire, threatening massive revenue losses in the future. To fill these gaps, they are acquiring suitable and innovative biotech companies with promising drug pipelines. Sometimes, however, they simply acquire technologies already worth billions. The current wave of acquisitions in the biotech sector is being driven by a combination of economic pressure, technological change toward AI and digitalization, and a weak financing environment for smaller biotech companies. After years of restraint and high volatility, fundamental valuation factors are back in focus. Investors are returning, creating a prosperous environment for those who jump on the bandwagon in time. We highlight a few ideas.
Read
Commented by André Will-Laudien on June 16th, 2025 | 07:15 CEST
Gaza, Iran, Ukraine – Conflicts are driving up metal prices! Rheinmetall, European Lithium, Hensoldt, and RENK
The problem is getting bigger! Strategic metals are currently having a massive impact on the geopolitical balance of power, as they play a decisive role in determining the economic and military capabilities of countries. Conflicts such as those in Gaza, Ukraine, and, more recently, Iran are exacerbating shortages because long-standing trade relationships can be terminated overnight. The concentration of metal production in a few countries makes supply chains vulnerable to political influence. Export restrictions, embargoes or targeted shortages imposed by China or Russia can lead to bottlenecks in consumer countries and severely affect the economy. We describe the current situation and offer solutions for dynamic investors.
Read
Commented by André Will-Laudien on June 16th, 2025 | 07:05 CEST
Iran, nuclear energy, oil – a revival for hydrogen! Nel ASA, Pure Hydrogen, Plug Power, and Oklo
The current attacks on Iran's nuclear facilities by Israel mark a new level of escalation in the Middle East. Of course, a radical regime like Iran cannot be allowed to conduct nuclear research. This region has already experienced too much terror. For the rest of the world, Israel's announcement, backed by the US, means another rise in oil prices, which will quickly shift the focus to alternative energies. Some companies have been promoting a future-oriented hydrogen infrastructure for years and are growing well. Australia's Pure Hydrogen is well advanced, while Nel ASA and Plug Power are still in the turnaround phase. There is currently a lot of movement on the capital markets. Risk-aware investors can benefit from the current trends with the right touch and timing. Where are the opportunities and risks?
Read
Commented by André Will-Laudien on June 13th, 2025 | 07:00 CEST
The three IT musketeers – AI, high tech, quantum computing! NetraMark Holdings, Bayer, Novo Nordisk, and D-Wave
A new edition of GTC 2025 is currently underway in the French capital, Paris, where NVIDIA CEO Jensen Huang spoke at length about the future of artificial intelligence. As usual, he also made some interesting comments about quantum computers. In the eyes of the NVIDIA CEO, quantum computer technology has reached a decisive turning point and will soon be able to solve some interesting problems that would take even NVIDIA's most advanced AI systems years of computing time to solve. The requirements go beyond pattern recognition, automation, and real-time decisions. Recently, AI has also been playing a significant role in medicine and pharmaceutical development. For some stocks, there is, therefore, a daily reason to reach new highs. Now is the time for investors to focus!
Read